SOUTH SAN FRANCISCO, Californië–(BUSINESS WIRE)– NanoTemper Technologies heeft vandaag de lancering aangekondigd van Spectral Shift-technologie binnen hun Dianthus-instrument, gebouwd om de meest uitdagende affiniteit gebaseerde screenings in het ontdekken van geneesmiddelen aan te kunnen. Deze baanbrekende technologie verwijdert de obstakels die wetenschappers ervaren die te maken hebben met echt complexe moleculaire interacties die vaak worden gezien bij uitdagende medicijnen en medicijndoelen zoals proteolyse-targeting chimera’s (PROTAC’s), intrinsically disordered proteins (IDP’s) of fragmentbibliotheken.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20220323005898/en/

NanoTemper Technologies Launches Spectral Shift, a Breakthrough Technology That Changes the Game for Affinity-Based Screenings

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– NanoTemper Technologies announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery. This breakthrough technology removes the roadblocks experienced by scientists dealing with really complex molecular interactions often seen in challenging drugs and drug targets like proteolysis-targeting chimeras (PROTACs), intrinsically disordered proteins (IDPs), or fragment libraries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005898/en/

NanoTemper’s Dianthus instrument includes breakthrough Spectral Shift technology to handle the most challenging affinity-based screenings in drug discovery. (Photo: Business Wire)

Scientists feel stuck because traditional screening methods like SPR or ITC haven’t been able to handle these difficult molecular interactions, or at best they offer very low-quality data. So, scientists end up making decisions with a lot of uncertainty since the results don’t clearly point to the best hits. Or, they spend too much time on lengthy assay development to characterize tricky interactions like ternary complexes and binary interactions with covalent ligands.

“Spectral Shift changes that,” comments Amit Gupta, Product Manager at NanoTemper. “Not only does it perform very precise measurements that generate such high-quality data for hit identification or lead optimization, but it requires little to no assay development.” These are huge wins for scientists working with undruggable targets like KRAS or STAT3. Finally experiencing increased success with screening campaigns and feeling confident they’re getting trustworthy results is such a relief.

“At NanoTemper, our vision is to help create a world where every disease is treatable, so it’s important that we create biophysical tools as quickly as possible to help scientists tackle their most challenging characterizations,” says Philipp Baaske, Co-founder and CEO of NanoTemper. “We put it in the hands of important biopharma companies, and early adoption of Spectral Shift in Dianthus was faster than we could have imagined — it validated the impact we believe it will have on the industry.”

Experience Spectral Shift and Dianthus for yourself; visit nanotempertech.com/dianthus.

About NanoTemper Technologies

Our mission at NanoTemper Technologies is to create biophysical tools for scientists in drug discovery and development who need to tackle challenging characterizations. Working with scientists striving to make a difference in the world gets us excited. If you’re facing challenges with affinity screening, molecular interactions, protein stability, protein expression, or protein quality, let’s talk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005898/en/

Contacts

John Valdez, Director of Marketing

john.valdez@nanotempertech.com
415.670.0424